


Extended Data Figure 2: CONSORT Diagram of Patient Disposition



This figure illustrates the flow chart of the study. A total of 77 patients were screened for the study. Sixty patients were enrolled in the study and received at least 1 dose of study treatment. Fifty-eight patients were eligible for efficacy analysis. ^a Reasons for ineligibility detailed in Appendix 1. ^b Received at least 1 dose of PCSK9 inhibitor Alirocumab 150mg SC q2weeks (home injection) +/- PD-1 inhibitor Cemiplimab 350mg IV q3 weeks